[go: up one dir, main page]

AR059197A1 - Derivados de indazolo piridina para el tratamiento de hiv - Google Patents

Derivados de indazolo piridina para el tratamiento de hiv

Info

Publication number
AR059197A1
AR059197A1 ARP070100307A ARP070100307A AR059197A1 AR 059197 A1 AR059197 A1 AR 059197A1 AR P070100307 A ARP070100307 A AR P070100307A AR P070100307 A ARP070100307 A AR P070100307A AR 059197 A1 AR059197 A1 AR 059197A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
alkyl
alkynyl
alkenyl
independently
Prior art date
Application number
ARP070100307A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR059197A1 publication Critical patent/AR059197A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente proporciona compuestos que demuestran efectos protectores en células objetivos de infeccion por VIH en una forma tal que se unen a un receptor de quimioquina, y que afecta la union del ligando natural o quimioquina a un receptor tal como CXCR4 de una célula objetivo. Reivindicacion 1: Un compuesto de la formula (1): caracterizado porque: t es 0, 1, o 2; cada R es independientemente H, alquilo de C1-8, alquenilo de C2-6, alquinilo C2-6, haloalquilo C1-8, cicloalquilo de C3-8, -RaAy, -RaOR10, -RaN(R10)2 o -RaS(O)qR10; cada R1 es independientemente halogeno, haloalquilo de C1-8, alquilo de C1-8, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-8, cicloalquenilo de C3-8, -Ay, -N(H)Ay, -Het, -N(H)Het, -OR10, -OAy, -OHet, - RaOR10, -N(R6)R7, -RaN(R6)R7, -RaC(O)R10, -C(O)R10, -CO2R10, -RaCO2R10, -C(O)N(R6)R7, -C(O)Ay, -C(O)Het, -S(O)2N(R6)R7, -S(O)qR10, -S(O)qAy, ciano, nitro, o azido; n es 0, 1, o 2; m es 0, 1, o 2; R2 es H, alquilo de C1-8, alquenilo de C2-6, alquinilo de C2-6, haloalquilo de C1-8, cicloalquilo de C3-8, -Racicloalquilo, -RaAy, -RaOR5, o -RaS(O)qR5, en donde R2 no es amina o alquilamina, o está sustituido con amina o alquilamina; R3 es halogeno, -N(R11)R12, -OR11, -C(O)R11, - C(O)N(R11)R12, -N(R11)C(O)R12, -N(R11)C(O)N(R11)R12, -N(R11)C(O)OR12, -S(O)2N(R11)R12, -N(R11)S(O)2R12, ciano, nitro, o azido; cada R4 es independientemente halogeno, haloalquilo de C1-8, alquilo de C1-8, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-8, cicloalquenilo de C3-8, -Ay, -N(H)Ay, Het, -N(H)Het, OR10, -OAy, -OHet, -RaOR10, -N(R6)R7, -RaN(R6)R7, -RaC(O)R10, -C(O)R10, -CO2R10, -RaCO2R10, -C(O)N(R6)R7, -C(O)Ay, -(O)Het, -S(O)2N(R6)R7, -S(O)qR10, -S(O)qAy, -S(O)NET, ciano, nitro, o azido; cada R5 es independientemente H, C1-8 alquilo, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-8, o -Ay; p es 0 o 1; Y es -NR10-, -O-, -C(O)NR10-, -N(R10)C(O)-, -C(O)-, -C(O)O-, -N(R10)C(O)N(R10)-, -S(O)q-, - S(O)qN(R10)-, o -N(R10)S(O)q-; X es -Ra N(R10)2, -AyN(R10)2, -RaAyN(R10)2, -AyRaN(R10)2, -RaAyRaN(R10)2, Het, -RaHet, -HetN(R10)2, -RaHetN(R10)2, -HetRaN(R10)2, -RaHetRaN(R10)2, -HetRaAy, o -HetRaHet; cada Ra es independientemente alquileno de C1-8, cicloalquileno de C3-8, alquenileno de C2-6, cicloalquenileno de C3-8, o alquinileno de C2-6, y está sustituido opcionalmente con uno o más de alquilo de C1-8, hidroxilo u oxo; cada R10 es independientemente H, C1-8 alquilo, cicloalquilo de C3-8, alquenilo de C2-6, alquinilo de C2-6, cicloalquenilo de C3-8, -Ra cicloalquilo, -RaOR5, RaN(R6)R7 o RaHet, cada R11 y r12 es independientemente H, C1-8 alquilo, cicloalquilo de C3-8, alquenilo de C2-6, alquinilo de C2-6, cicloalquenilo de C3-8, -Ra cicloalquilo, -RaOR5, cada uno de R6 y R7 se selecciona independientemente de H, alquilo de C1-8, C1-8 alquenilo, alquinilo de C2-6, cicloalquilo de C3-8, cicloalquenilo de C3-8, -Ra cicloalquilo, -RaOR5, -RaN(R8)R9, -Ay, -Het, -RaAy, -RaHet, - C(O)R5 o -S(O)qR5; cada uno de R8 y R9 se selecciona independientemente de H o C1-8 alquilo; cada q es independientemente 0, 1, o 2; cada Ay representa independientemente un grupo arilo de C3-10 sustituido opcionalmente con uno o más de alquilo de C1-8, alquenilo de C2-6, alquinilo de C2-6, alcoxi de C1-8, hidroxilo, halogeno, haloalquilo de C1-8, cicloalquilo de C3-8, cicloalcoxi de C3-8, ciano, amida, amino, y alquilamino de C1-8; y cada Het representa independientemente un grupo heterociclilo o heteroarilo de C3-7 sustituido opcionalmente con uno o más alquilo de C1-8, alquenilo de C2-6, alquinilo de C2-6, alcoxi de C1-8, hidroxilo, halogeno, haloalquilo de C1-8, cicloalquilo de C3-8, cicloalcoxi de C3-8, ciano, amida, amino, y alquilamino de C1-8; o sus derivados aceptables para uso farmacéutico.
ARP070100307A 2006-01-25 2007-01-24 Derivados de indazolo piridina para el tratamiento de hiv AR059197A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76189206P 2006-01-25 2006-01-25

Publications (1)

Publication Number Publication Date
AR059197A1 true AR059197A1 (es) 2008-03-19

Family

ID=38309924

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100307A AR059197A1 (es) 2006-01-25 2007-01-24 Derivados de indazolo piridina para el tratamiento de hiv

Country Status (7)

Country Link
US (1) US20100280010A1 (es)
EP (1) EP1984376A4 (es)
JP (1) JP2009524690A (es)
AR (1) AR059197A1 (es)
PE (1) PE20070946A1 (es)
TW (1) TW200738711A (es)
WO (1) WO2007087549A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005478A (es) 2006-11-27 2009-08-12 Lundbeck & Co As H Derivados de heteroarilamida.
EP2592082A1 (en) 2007-04-10 2013-05-15 H. Lundbeck A/S Heteroaryl amide analogues as p2x7 antagonists
BRPI0820171B8 (pt) 2007-11-16 2021-05-25 Rigel Pharmaceuticals Inc compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos
EP2231666B1 (en) 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
CA2722139C (en) 2008-04-23 2017-04-11 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
CN102131805A (zh) 2008-06-20 2011-07-20 百时美施贵宝公司 用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物
EP2467137A1 (en) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103570683B (zh) * 2012-07-30 2018-04-17 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
CN104083386B (zh) * 2014-07-08 2016-07-06 滨州医学院 安普那韦在制备预防或治疗急性肺损伤/急性呼吸窘迫综合征和肺纤维化的药物中的应用
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112018002571B1 (pt) 2015-08-07 2022-04-05 Bayer Cropscience Aktiengesellschaft Derivados heterocíclicos condensados substituídos por 2-(het)arila como agentes de controle de praga, seu uso, formulação agroquímica, e método para controlar pragas animais
JP6980649B2 (ja) 2015-09-14 2021-12-15 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10450318B2 (en) 2015-12-15 2019-10-22 Bristol-Myers Squibb Company CXCR4 receptor antagonists
EP3393468B1 (en) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN116554168B (zh) 2016-06-21 2025-09-23 X4制药有限公司 Cxcr4抑制剂及其用途
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3585387A4 (en) * 2017-02-21 2020-08-12 Emory University CHEMIOKIN CXCR4 RECEIVER MODULATORS AND THEIR USES
WO2019126106A1 (en) * 2017-12-19 2019-06-27 X4 Pharmaceuticals, Inc. Acyclic cxcr4 inhibitors and uses thereof
US11649235B2 (en) 2018-03-19 2023-05-16 Emory University Pan-tropic entry inhibitors
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN110437262A (zh) * 2019-08-02 2019-11-12 桂林理工大学 以DMF和碘化铵为氰基化试剂构建2-苯基苯并[d]咪唑[2,1-b]噻唑-3-腈
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
EP4311828A1 (en) * 2022-07-26 2024-01-31 Basf Se A process for the photolytic chlorination of 3-halopyridine with molecular chlorine
WO2023241960A1 (en) * 2022-06-15 2023-12-21 Basf Se A process for the photolytic chlorination of 3-halopyridine with molecular chlorine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2244378A1 (en) * 1996-01-23 1997-07-31 The Regents Of The University Of Michigan Modified benzimidazole nucleosides as antiviral agents
ATE335733T1 (de) * 2000-09-15 2006-09-15 Anormed Inc Chemokin rezeptor bindenden heterozyklischen verbindungen
KR20030029997A (ko) * 2000-09-15 2003-04-16 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
CA2520259A1 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
JP4870660B2 (ja) * 2004-03-15 2012-02-08 アノーメッド インコーポレイティド Ｃｘｃｒ４アンタゴニストの合成プロセス
MX2007002679A (es) * 2004-09-02 2007-05-16 Smithkline Beecham Corp Compuestos quimicos.
EP1793825A4 (en) * 2004-09-24 2009-12-09 Smithkline Beecham Corp CHEMICAL COMPOUNDS
EP1919872A4 (en) * 2005-08-31 2009-08-05 Smithkline Beecham Corp CHEMICAL COMPOUNDS

Also Published As

Publication number Publication date
TW200738711A (en) 2007-10-16
EP1984376A4 (en) 2009-04-08
US20100280010A1 (en) 2010-11-04
EP1984376A2 (en) 2008-10-29
WO2007087549A3 (en) 2007-12-13
WO2007087549A2 (en) 2007-08-02
JP2009524690A (ja) 2009-07-02
PE20070946A1 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
AR059197A1 (es) Derivados de indazolo piridina para el tratamiento de hiv
AR050302A1 (es) Derivados de imidazo[1,2-a]piridina
AR050522A1 (es) Derivados de bencimidazol como moduladores de la actividad de los receptores de quimioquina; composiciones farmaceuticas que los contienen; metodos para su preparacion y su uso en la fabricacion de medicamentos para el tratamiento contra infecciones por hiv
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
CO6270227A2 (es) Derivados de quinazolinadiona su preparacion y sus aplicaciones terapeuticas
GT200500183A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR078786A1 (es) Derivados de la cromenona
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
AR062526A1 (es) DERIVADOS DE 4-(3-METILMORFOLIN-4-IL)PIRIMIDINA Y MORFOLIN-4-IL-PIRIMIDINA COMO INHIBIDORES DE MTOR QUINASA Y PI3K, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y EL USO DE LOS MISMOS EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE DIVERSOS TIPOS DE CANCER.
AR070127A1 (es) Pirrolo - pirimidinas y pirrolo -piridinas
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
AR061057A1 (es) Derivados de pirazolo(3,4-d)pirimidina utiles para desordenes respiratorios
AR077999A1 (es) Antagonistas de pirimidin y triazin-hepcidina
PE20120106A1 (es) Moduladores de receptores tipo toll
AR059037A1 (es) Compuestos para el tratamiento de trastornos inflamatorios
AR061620A1 (es) Suspensiones acuosas de tmc278
BRPI0619255A8 (pt) Composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer
AR082995A1 (es) Profarmacos que comprenden un conjugado de conector de exendina
AR066121A1 (es) Derivados de pirimidinona y metodos para su uso
AR075894A1 (es) Derivados oxidados de triazolilpurinas utiles como ligandos de receptor de adenosina a2a y su uso como medicamentos.
AR060590A1 (es) Compuestos imidazo
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
AR060914A1 (es) Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico.
PE20071311A1 (es) Compuestos 8-azabiciclo[3.2.1]octano como antagonistas del receptor opioide mu

Legal Events

Date Code Title Description
FA Abandonment or withdrawal